Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure
Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent manifestation of PH but lacks any approved treatment. Activin receptor type IIA-Fc fusion protein (ActRIIA-Fc) was found previously to be efficacious in experimental and human pulmonary arterial hypertension (PAH). Here w...
Main Authors: | Sachindra R. Joshi, Elif Karaca Atabay, Jun Liu, Yan Ding, Steven D. Briscoe, Mark J. Alexander, Patrick Andre, Ravindra Kumar, Gang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1064290/full |
Similar Items
-
Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study
by: Xiao-mei Huang, et al.
Published: (2024-01-01) -
Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left‐sided heart diseases
by: Taijyu Satoh, et al.
Published: (2023-12-01) -
Association of ambient temperature and acute heart failure with preserved and reduced ejection fraction
by: Takahiro Jimba, et al.
Published: (2022-10-01) -
Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023-08-01) -
Prognostic Role of Pulmonary Function in Patients With Heart Failure With Reduced Ejection Fraction
by: Hao‐Chih Chang, et al.
Published: (2022-04-01)